BR0210149A - Pródrogas ativadas por deformilase de peptìdeo - Google Patents

Pródrogas ativadas por deformilase de peptìdeo

Info

Publication number
BR0210149A
BR0210149A BR0210149-1A BR0210149A BR0210149A BR 0210149 A BR0210149 A BR 0210149A BR 0210149 A BR0210149 A BR 0210149A BR 0210149 A BR0210149 A BR 0210149A
Authority
BR
Brazil
Prior art keywords
peptide deformylase
microorganism
gram
vivo
development
Prior art date
Application number
BR0210149-1A
Other languages
English (en)
Inventor
Maria Vladimir Sergeeva
Venkata Ramana Doppalapudi
Original Assignee
Newbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiotics Inc filed Critical Newbiotics Inc
Publication of BR0210149A publication Critical patent/BR0210149A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"PRóDROGAS ATIVADAS POR DEFORMILASE DE PEPTìDEO". Esta invenção fornece um método para inibir o desenvolvimento de um microorganismo que expressa Deformilase de Peptídeo contatando-se o microorganismo com uma quantidade eficaz do composto descrito aqui. Este método inibe o desenvolvimento de microorganismos gram-positivos e gram-negativos, por exemplo, S. aureus, S. epidermidis, K pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzae e P.aeruginosa. Este método pode ser praticado in vitro, ex vivo e in vivo. Também fornecido é um método para aliviar os sintomas de uma infecção por um microorganismo expressando Deformilase de Peptídeo em um indivíduo administrando-se ou liberando-se para o indivíduo uma quantidade eficaz do composto descrito acima.
BR0210149-1A 2001-05-09 2002-05-09 Pródrogas ativadas por deformilase de peptìdeo BR0210149A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29009901P 2001-05-09 2001-05-09
PCT/US2002/014500 WO2002089739A2 (en) 2001-05-09 2002-05-09 Peptide deformylase activated prodrugs

Publications (1)

Publication Number Publication Date
BR0210149A true BR0210149A (pt) 2004-06-29

Family

ID=23114523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210149-1A BR0210149A (pt) 2001-05-09 2002-05-09 Pródrogas ativadas por deformilase de peptìdeo

Country Status (7)

Country Link
US (1) US7163923B2 (pt)
EP (1) EP1399467A4 (pt)
JP (1) JP4109123B2 (pt)
AU (1) AU2002314773B2 (pt)
BR (1) BR0210149A (pt)
CA (1) CA2447470A1 (pt)
WO (1) WO2002089739A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482029A1 (en) * 2002-04-18 2003-10-30 Maria V. Sergeeva Peptide deformylase activated prodrugs
BR0315537A (pt) 2002-11-14 2005-09-27 Celmed Oncology Usa Inc Pró-drogas ativadas por peptìdeo desformilase
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
SI3570844T1 (sl) 2017-01-20 2024-01-31 Arcus Biosciences, Inc. Azolopirimidin za zdravljenje z rakom povezanih motenj
PL3634417T3 (pl) 2017-05-17 2023-09-25 Arcus Biosciences, Inc. Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053638A (en) * 1970-05-06 1977-10-11 William Wrigley Jr. Company Anticaries confectioneries and oral health products
JPS5223001A (en) * 1975-08-14 1977-02-21 Ajinomoto Co Inc Process for elimination of formyl group
US4083974A (en) * 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
HU181013B (en) 1980-01-25 1983-05-30 Gyogyszerkutato Intezet Process for preparing new enkephalin analogues
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US4415590A (en) * 1982-04-26 1983-11-15 Betamed Pharmaceuticals, Inc. Herpes treatment
US5350681A (en) * 1986-08-18 1994-09-27 The Coca-Cola Company Enzymatic membrane method for the synthesis and separation of peptides
US5274113A (en) * 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
DE69518631T2 (de) * 1994-03-10 2001-01-11 Searle & Co L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren
ZA962455B (en) * 1995-03-31 1996-10-02 B Eugene Guthery Fast acting and persistent topical antiseptic
US5842441A (en) * 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
WO1998013513A2 (en) * 1996-09-24 1998-04-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
WO1998013059A1 (en) * 1996-09-27 1998-04-02 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1999008110A1 (en) 1997-08-08 1999-02-18 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
US6448058B1 (en) 1997-09-12 2002-09-10 Versicor, Inc. Methods for solid phase synthesis of mercapto compounds and derivatives, combinatorial libraries thereof and compositions obtained thereby
US6159706A (en) 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
EP1167972B1 (en) 1998-01-23 2017-03-08 Kiadis Pharma Intellectual Property B.V. Enzyme catalyzed therapeutic agents
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
ATE429438T1 (de) 1999-07-22 2009-05-15 Celmed Oncology Usa Inc Enzym katalisierte therapeutische aktivierung
CA2482029A1 (en) 2002-04-18 2003-10-30 Maria V. Sergeeva Peptide deformylase activated prodrugs
BR0315537A (pt) 2002-11-14 2005-09-27 Celmed Oncology Usa Inc Pró-drogas ativadas por peptìdeo desformilase

Also Published As

Publication number Publication date
WO2002089739A2 (en) 2002-11-14
WO2002089739A3 (en) 2003-08-21
EP1399467A4 (en) 2004-09-15
US7163923B2 (en) 2007-01-16
CA2447470A1 (en) 2002-11-14
US20030091587A1 (en) 2003-05-15
JP4109123B2 (ja) 2008-07-02
EP1399467A2 (en) 2004-03-24
JP2005505502A (ja) 2005-02-24
AU2002314773B2 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
Müller et al. Poorly cross-linked peptidoglycan in MRSA due to mecA induction activates the inflammasome and exacerbates immunopathology
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
DE69331953D1 (de) Antimikrobielle polypeptide
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
GEP20053429B (en) 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
BR0111980A (pt) Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda
BR0214736A (pt) Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR9811535A (pt) Composições farmacêuticas contendo lisostafina sozinha ou em combinação com um antibiótico para o tratamento de infecções por estafilocócico
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
MX2007010478A (es) Glicopeptidos semisinteticos con actividad antibiotica.
BR0210149A (pt) Pródrogas ativadas por deformilase de peptìdeo
BR0116756A (pt) Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma
Sztukowska et al. Peptide and non‐peptide mimetics as potential therapeutics targeting oral bacteria and oral biofilms
Steinstraesser et al. Protegrin-1 enhances bacterial killing in thermally injured skin
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
BR0309418A (pt) pró-drogas ativadas por peptìdeos deformilase
ATE285786T1 (de) Säugetierabkömmliche peptide zur behandlung von mikrobiellen infektionen
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
BR0317947A (pt) Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CELMED ONCOLOGY (USA), INC. (CA)

Free format text: ALTERADO DE: NEWBIOTICS, INC.

B25G Requested change of headquarter approved

Owner name: CELMED ONCOLOGY (USA), INC. (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050094969/RJ DE 08/09/2005.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.